Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aduro Biotech, Inc. (NASDAQ: ADRO).

Full DD Report for ADRO

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADRO)

Detailed Research: Economic Perspectives on Churchill Downs, Nordic American Tankers, News Corporation, Aduro Biotech, MannKind, and Crane - What Drives Growth in Today's Competitive Landscape
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Churchill Downs, Incorporated (NASDAQ:CHDN), Nordic American Tankers Limit...
Source: GlobeNewswire
Date: May, 17 2018 08:00
Celldex Trying To Regroup With Its Early-Stage Assets
It was clear back in April that Celldex Therapeutics ( CLDX ) would be restructuring and realigning its priorities after the failure of its Phase III METRIC study of glembatumumab ("glemba") in triple-negative breast cancer, and after the first quarter earnings report, investors have a clear...
Source: SeekingAlpha
Date: May, 11 2018 11:59
Aduro Biotech to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
BERKELEY, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Thursday, ...
Source: GlobeNewswire
Date: May, 10 2018 16:01
Aduro Biotech beats by $0.07, beats on revenue
Aduro Biotech (NASDAQ: ADRO ): Q1 EPS of -$0.28 beats by $0.07 . More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 02 2018 16:58
Aduro Biotech Reports First Quarter 2018 Financial Results
BERKELEY, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the first quarter ended March 31, 2018. Net loss for the first quarter of 2018 was $21.5 million, or $0.28 per share, compared to net loss of $21.8 million, or $0.32 per...
Source: GlobeNewswire
Date: May, 02 2018 16:01
Aduro Biotech Presents Early Observations From its Personalized Neoantigen-based pLADD Therapy Clinical Study at European Neoantigen Summit
BERKELEY, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today presented preliminary observations from a case study of a patient with metastatic colorectal cancer treated in Aduro’s ongoing Phase 1 study of its personalized neoantigen-based immunotherapy...
Source: GlobeNewswire
Date: April, 26 2018 08:00
3 Things In Biotech, April 20: AstraZeneca Re-Enters The Big Leagues, Aduro Looks Ahead, Lilly Looks Close
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
Source: SeekingAlpha
Date: April, 21 2018 08:00
Aduro Biotech Highlights Preclinical Data for Three Programs Reported at the American Association for Cancer Research Annual Meeting
BERKELEY, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that data from three of the company’s programs were presented at the American Association for Cancer Research (AACR) this week. The poster presentations detailed: Updated precli...
Source: GlobeNewswire
Date: April, 17 2018 16:01
Aduro Biotech (ADRO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
The following slide deck was published by Aduro Biotech in conjunction with this Read more ...
Source: SeekingAlpha
Date: April, 10 2018 12:20
Key events next week - healthcare
Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 06 2018 07:14

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-178.158.108.2758.05551,846
2017-02-0211.8511.7511.8511.575295,490
2017-02-0111.8011.9012.0011.60349,086
2017-01-3111.0511.8511.92510.75211,478
2017-01-3011.0511.1511.2010.75213,846

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1754,490112,26148.5387Short
2018-08-1622,15352,04642.5643Short
2018-08-1528,29764,74543.7053Short
2018-08-149,47242,02822.5374Cover
2018-08-1310,37337,57827.6039Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADRO.


About Aduro Biotech, Inc. (NASDAQ: ADRO)

Logo for Aduro Biotech, Inc. (NASDAQ: ADRO)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $661,333,277 - 05/14/2018
  • Issue and Outstanding: 78,730,152 - 04/27/2018

 


Recent Filings from (NASDAQ: ADRO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 20 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 20 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 12 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 12 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 01 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: ADRO)

Daily Technical Chart for (NASDAQ: ADRO)


Stay tuned for daily updates and more on (NASDAQ: ADRO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ADRO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADRO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ADRO and does not buy, sell, or trade any shares of ADRO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/